The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGSS.L Regulatory News (GSS)

  • There is currently no data for GSS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison review on Genesis Emerging Markets Fund

16 Oct 2019 15:57

RNS Number : 1321Q
Genesis Emerging Markets Fund Ld
16 October 2019
 

 

London, UK, 16 October 2019

Edison issues review on Genesis Emerging Markets Fund (GSS)

Genesis Emerging Markets Fund (GSS) was launched in 1989 and is one of the first funds listed in the UK focused on this asset class. Its objective is to deliver capital growth over the long term through investing in high-quality companies listed in, or with substantial exposure to, emerging markets. Unconstrained by index considerations, the portfolio reflects the highest-conviction investment ideas from a team of emerging markets specialists. The fund has a solid long-term track record of outperforming the MSCI Emerging Markets Index and, over the past 10 years, has delivered an annualised NAV total return of 8%. Investor appetite for the asset class is currently subdued; however, the manager has a long-term investment horizon and is finding exciting opportunities.

 

GSS trades on a 10.5% discount to its cum-income NAV, which is narrower than its three-year average of 12.2%. The board recently introduced several measures to broaden the appeal of the fund, including a further tender offer if the fund's NAV total return over five years to June 2021 does not exceed that of its benchmark. Combined with continued solid performance and the potential for improved sentiment towards emerging markets, there is scope for the discount to narrow.

Click here to view the full report.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Helena Coles, +44 (0)20 3681 2522

Sarah Godfrey, +44 (0)20 3681 2519

investmenttrusts@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-investment-research 

Twitter www.twitter.com/Edison_Inv_Res 

YouTube www.youtube.com/edisonitv 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFFDFLMFUSEIS
Date   Source Headline
27th Jan 202110:48 amRNSNet Asset Value(s)
26th Jan 202110:45 amRNSNet Asset Value(s)
25th Jan 202110:28 amRNSNet Asset Value(s)
22nd Jan 202110:25 amRNSNet Asset Value(s)
21st Jan 202110:35 amRNSNet Asset Value(s)
20th Jan 202111:13 amRNSNet Asset Value(s)
19th Jan 202110:33 amRNSNet Asset Value(s)
19th Jan 202110:06 amRNSCompliance with US Executive Order 13959
18th Jan 202110:41 amRNSNet Asset Value(s)
15th Jan 202110:53 amRNSNet Asset Value(s)
14th Jan 202111:23 amRNSNet Asset Value(s)
13th Jan 202111:12 amRNSNet Asset Value(s)
12th Jan 202110:46 amRNSNet Asset Value(s)
11th Jan 202110:43 amRNSNet Asset Value(s)
8th Jan 202111:04 amRNSNet Asset Value(s)
7th Jan 202111:30 amRNSNet Asset Value(s)
6th Jan 202110:34 amRNSNet Asset Value(s)
5th Jan 202111:06 amRNSNet Asset Value(s)
4th Jan 202112:57 pmRNSNet Asset Value(s)
4th Jan 20217:00 amRNSTotal Voting Rights
31st Dec 202010:59 amRNSNet Asset Value(s)
30th Dec 202011:09 amRNSNet Asset Value(s)
29th Dec 202011:49 amRNSNet Asset Value(s)
24th Dec 202010:40 amRNSNet Asset Value(s)
23rd Dec 202011:11 amRNSNet Asset Value(s)
22nd Dec 202010:55 amRNSNet Asset Value(s)
21st Dec 202010:40 amRNSNet Asset Value(s)
18th Dec 202010:36 amRNSNet Asset Value(s)
17th Dec 202010:49 amRNSNet Asset Value(s)
16th Dec 202010:18 amRNSNet Asset Value(s)
15th Dec 202011:27 amRNSNet Asset Value(s)
14th Dec 202011:39 amRNSNet Asset Value(s)
11th Dec 202011:17 amRNSNet Asset Value(s)
10th Dec 202010:30 amRNSNet Asset Value(s)
9th Dec 202010:39 amRNSNet Asset Value(s)
8th Dec 202010:20 amRNSNet Asset Value(s)
7th Dec 202010:42 amRNSNet Asset Value(s)
4th Dec 202011:07 amRNSNet Asset Value(s)
3rd Dec 202011:06 amRNSNet Asset Value(s)
2nd Dec 202011:22 amRNSNet Asset Value(s)
1st Dec 202012:42 pmRNSNet Asset Value(s)
1st Dec 20208:00 amRNSEdison review on Genesis Emerging Markets Fund
30th Nov 20205:55 pmRNSTotal Voting Rights
30th Nov 202011:22 amRNSNet Asset Value(s)
27th Nov 202012:12 pmRNSNet Asset Value(s)
26th Nov 202012:36 pmRNSNet Asset Value(s)
25th Nov 202010:46 amRNSNet Asset Value(s)
24th Nov 202011:02 amRNSNet Asset Value(s)
23rd Nov 202011:26 amRNSNet Asset Value(s)
20th Nov 202011:47 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.